Aquarius Surgical Technologies Inc. (formerly Aquarius Coatings Inc.)：高管交易动态
Aquarius Surgical Technologies Inc. (formerly Aquarius Coatings Inc.)归属医疗保健行业。公司董事和高级管理人员通过SEDI申报交易。Aquarius Surgical Technologies Inc. (formerly Aquarius Coatings Inc.)已超过一年没有高管申报，最近一份可追溯到2023年3月31日。
完整历史始于2017年，共计16笔买入、0笔卖出。
数据来源：高管申报（SEDI）。过往交易不代表未来收益。
该评分只在所属市场内对买入进行排名。仅在经过回测的策略范围内的交易所提供建议仓位；其他市场的信号仍处于观察状态。并非投资建议。
财务数据
财年 2026财年截至 2026年3月 · cache
- 4,598,704 股@ CA$0.0377.6% 占其流量股票TSXSEDI:4105927
- 3,920,000 股@ CA$0.05股票TSXSEDI:4044051
- 169,721 股股票TSXSEDI:3921712
- 169,721 股股票TSXSEDI:3921722
- 26,251 股股票TSXSEDI:3921729
- 88,000 股股票TSXSEDI:3919323
- 154,714 股股票TSXSEDI:3919333
- 88,000 股股票TSXSEDI:3919316
- 股票TSXSEDI:3919303
- 股票TSXSEDI:3916419
- 100,000 股@ CA$0.065100.0% 占其流量股票TSXSEDI:3916420
- 股票TSXSEDI:3915776
- 股票TSXSEDI:3915753
- 股票TSXSEDI:3915319
- 股票TSXSEDI:3915311
- 100,000 股@ CA$0.065100.0% 占其流量股票TSXSEDI:3915779
- 100,000 股@ CA$0.065100.0% 占其流量股票TSXSEDI:3915313
- 100,000 股@ CA$0.065100.0% 占其流量股票TSXSEDI:3915321
- 100,000 股@ CA$0.065100.0% 占其流量股票TSXSEDI:3915302
- 10,000 股@ CA$0.328.3% 占其流量股票TSXSEDI:3433940标准退出：2019年5月5日 (T+90)
- 14,500 股@ CA$0.30股票TSXSEDI:3313136标准退出：2019年5月7日 (T+90)
- 1,000 股@ CA$0.30股票TSXSEDI:3310221标准退出：2019年5月2日 (T+90)
- 21,000 股@ CA$0.30股票TSXSEDI:3308967标准退出：2019年5月1日 (T+90)
- 4,500 股@ CA$0.29股票TSXSEDI:3299709标准退出：2019年4月10日 (T+90)
- 8,000 股@ CA$0.285.4% 占其流量股票TSXSEDI:3297831标准退出：2019年4月8日 (T+90)
40 条申报中的 25 条
About Aquarius Surgical Technologies Inc. (formerly Aquarius Coatings Inc.)
David John Hennigar, a director and senior officer of Aquarius Surgical Technologies Inc. (formerly Aquarius Coatings Inc.), signs 26 of the 39 filings in the record, of which 15 purchases. He also made the largest, EUR 10,007 on September 13, 2018, the day Gary Norman Van Nest, a director, bought EUR 5,003. Between September 13, 2018 and September 20, 2018, 2 filers bought EUR 25,430. David John Hennigar also bought EUR 3,941 on September 19, 2018.
The record's 16 purchases (10 with an amount) total EUR 32,018, with a median of EUR 2,550. No sale is filed; the rest is 5 grants and 18 filings of another kind. Charlotte Marie Janssen, Rajiv Kumar Singal and Stanley Joseph Swierzewski, directors, have no purchase.
展开全文收起
Filings, published from March 31, 2017 to March 31, 2023, are concentrated in 2022 (17) and 2018 (11), against 2 in 2017, 8 in 2019 and one in 2023. The Toronto company, classified under health care, is valued at CAD 413,988 and insiders hold 51.4% of it. Across 10 purchases with a 90-day return, the stored median is -37.5% (past results on record, not a forecast). No filing falls within the last twelve months.
